BGI officials hike equity stakes as prices fall

Chinese genomics giant BGI, known as the Beijing Genomics Institute previously, announced on Tuesday that seven of its executives have decided to increase their equity holdings in the company, after a two-day stock slump triggered by a series of reports attacking its credibility.

A report from tech news site huxiu revealed some newborns with defects were previously assessed as low risk by BGI's DNA-based non-invasive prenatal testing. It took the case of a boy with mental disabilities and physical deformities in Hunan province as an example.

The report also criticized some hospitals and doctors in China, saying they rely too much on BGI's tests, meaning traditional methods, such as amniocentesis, are neglected.